`
`
`
`
`
`Entered: February 28, 2017
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`NOVARTIS AG
`Patent Owner
`_______________________
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`_______________________
`
`Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`
`
`PETITIONER’S OBJECTIONS TO PATENT OWNER’S EVIDENCE
`
`
`
`
`
`
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`Under 37 C.F.R. § 42.64(b)(1), Petitioner Par Pharmaceutical, Inc.
`
`(“Petitioner”) submits the following objections to evidence submitted by Patent
`
`Owner Novartis AG (“Patent Owner”). Petitioner’s objections apply equally to
`
`Patent Owner’s reliance on this evidence in any subsequently-filed documents or
`
`further proceedings in this matter. These objections are timely, having been filed
`
`and served within ten business days of the institution of the trial.
`
`
`
`Notwithstanding these objections, Petitioner expressly reserves the right to
`
`rely on any evidence submitted by Patent Owner, including on the ground that such
`
`evidence constitutes a party admission.
`
`Objections
`
`Exhibit 2001 (Kulke Decl.)
`
`Petitioner objects to this document as inadmissible hearsay under FRE 801
`
`and 802 that does not fall under any exceptions, including those of FRE 803, 804,
`
`805, or 807, and as improper expert testimony under FRE 702, 703, and 37 C.F.R.
`
`§ 42.65, to the extent it impermissibly acts as a conduit for hearsay, including the
`
`hearsay objected to herein, and does not rely on the kinds of facts or data that
`
`experts in the relevant field would reasonably rely on in forming an opinion on the
`
`subject without providing the underlying facts, data, and other required disclosures.
`
`Petitioner objects to this document for lack of foundation and lack of
`
`personal knowledge, as improper expert testimony under FRE 702, 703, and 37
`
`1
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`C.F.R. § 42.65, and as improper lay testimony under FRE 701, to the extent it
`
`offers testimony in areas outside of Dr. Kulke’s area of expertise or fails to
`
`properly provide the underlying facts, data, and other required disclosures,
`
`including but not limited to the portions at paragraphs 5 and 89-96 purporting to
`
`address whether the FDA approval and the underlying clinical trial data from the
`
`RADIANT-3 clinical trial would have been unexpected to a person of ordinary
`
`skill as of November 2005.
`
`Exhibits 2003 (Seeley) and 2021 (Remington’s)
`
`Petitioner objects to these documents under FRE 106 (completeness), as the
`
`documents are incomplete and only include select portions of larger documents
`
`that in fairness ought to be considered in connection with these exhibits.
`
`To the extent Patent Owner relies on these exhibits for the truth of the matter
`
`asserted, Petitioner objects to them as inadmissible hearsay under FRE 801 and
`
`802 that does not fall under any exceptions, including FRE 803, 804, 805, or 807.
`
`Exhibit 2016 (Novartis Press Release)
`
`Petitioner objects to this document as not properly authenticated under FRE
`
`901 because Patent Owner has not presented any evidence that the document is
`
`authentic nor that the document is self-authenticating under FRE 902.
`
`Petitioner objects to this as inadmissible hearsay under FRE 801 and 802
`
`that does not fall under any exceptions, including FRE 803, 804, 805, or 807.
`
`2
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`Exhibits 2017 (Ritchel) and 2018 (WHO)
`
`Petitioner objects to these documents as inadmissible hearsay under FRE
`
`801 and 802 that does not fall under any exceptions, including those of FRE 803,
`
`804, 805, or 807.
`
`Petitioner objects to these documents under FRE 106 (completeness), as the
`
`documents are incomplete and only includes select portions of larger documents
`
`that in fairness ought to be considered in connection with these exhibits.
`
`Exhibits 2024 (Ratain Trial Tr. I), 2025 (Ratain Trial Tr. II), and 2026
`(Ratain Dep. Tr.)
`
`Petitioner objects to these documents as inadmissible hearsay under FRE
`
`801 and 802 that does not fall under any exceptions, including FRE 803, 804, 805,
`
`or 807.
`
`Petitioner objects to these documents under FRE 106 (completeness), as the
`
`documents are incomplete and only include select portions of larger documents
`
`that in fairness ought to be considered in connection with these exhibits.
`
`Exhibits 2010 (Pazdur), 2011 (Kouvaraki), 2015 (Margolin), 2019 (Gemzar®
`Prescribing Information 2005), 2022 (Yao), 2027 (Dancey 2005), and 2028
`(Duran 2006)
`
`Petitioner objects to these documents under FRE 401 and 402, as the
`
`documents do not have a tendency to make the facts for which they are offered any
`
`more or less probable than those facts would otherwise be.
`
`Petitioner objects to these documents under FRE 403, as any probative value
`
`3
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`is substantially outweighed by a danger of unfair prejudice, confusing the issues,
`
`wasting time, and needlessly presenting cumulative evidence.
`
`To the extent Patent Owner relies on the contents of these exhibits for the
`
`truth asserted, Petitioner objects to these documents as inadmissible hearsay under
`
`FRE 801 and 802 that does not fall under any exceptions, including FRE 803, 804,
`
`805, or 807.
`
`Exhibits 2005 (Laughlin Cancer Glossary), 2008 (Motzer), 2012 (Delaunoit),
`2013 (Kulke 2003), 2014 (Kulke 2004), 2020 (Kulke 1999), and 2023 (Kola &
`Landis)
`
`To the extent Patent Owner relies on the contents of these exhibits for the
`
`truth asserted, Petitioner objects to them as hearsay not falling under any
`
`exception. These exhibits contain out of court statements by non-parties, but
`
`Patent Owner does not provide any basis for the PTAB to conclude that they fall
`
`within any hearsay objection.
`
`
`
`
`
`
`
`
`
`
`
`Dated: February 28, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Daniel G. Brown/
`
`
`
`
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner
`
`4
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 28th day of
`
`February, 2017, a copy of Petitioner’s Objections to Patent Owner’s Evidence
`
`was served by electronic mail on Patent Owner’s lead and backup counsel at the
`
`following email addresses:
`
`Nicholas N. Kallas (Reg. No. 31,530)
`Raymond R. Mandra (Reg. No. 34,382)
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`ZortressAfinitorIPR@fchs.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Daniel G. Brown/
`
`
`
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`